Verrica Pharmaceuticals (VRCA) investor relations material

Executive summary

• Achieved significant transformation in 2025, doubling core product revenue and reducing costs, while advancing clinical and commercial initiatives.

• Total revenue for 2025 rose to $35.6 million, a 370% increase year-over-year, driven by YCANTH and milestone payments.

• Implemented an optimized commercial strategy, resulting in over 130% revenue growth for YCANTH and a 40% reduction in SG&A expenses year-over-year.

• Strengthened financial position through $18M in non-dilutive milestone payments and a $50M equity raise, enabling debt retirement and extending cash runway into 2027.

• No outstanding debt as of year-end 2025; cash runway extended into Q1 2027.

Financial highlights

• Q4 2025 revenue was $5.1M, up from $0.3M in Q4 2024; full-year 2025 revenue reached $35.6M, a 370% increase year-over-year.

• Net YCANTH revenue for 2025 was $15.3M, with $20.3M from Torii milestone and collaboration revenue.

• Gross product margin improved to 85.7% for 2025, up from 71.8% in 2024.

• GAAP net loss for 2025 was $17.9M ($1.68/share), significantly reduced from $76.6M ($14.78/share) in 2024; non-GAAP net loss was $13.2M ($1.24/share) vs. $64.6M ($12.47/share) prior year.

• Cash and equivalents at year-end 2025 were $30.1M, expected to fund operations into 2027.

Outlook and guidance

• Anticipates continued growth in YCANTH driven by expanded sales force, new access initiatives, and label expansion opportunities.

• Expects to submit a marketing authorization application for YCANTH in the EU within 12 months, with potential for commercialization partnerships.

• Phase 3 program for YCANTH in common warts underway; second Phase 3 study to start in mid-2026.

• Advancing VP-315 to Phase 3 for basal cell carcinoma in 2026.

• Regulatory alignment in the EU allows for YCANTH approval filing without additional clinical studies.